GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.

Trial Details

NCT ID
NCT04864054
Phase
PHASE1 / PHASE2
Sponsor
Eureka Therapeutics Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ECT204 T cells
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Buffalo, New York, United States|42.88645,-78.87837
  • The Bronx, New York, United States|40.84985,-73.86641
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Histologically confirmed HCC, that is unresectable, recurrent, and/or metastatic.
  • GPC3-positive tumor expression confirmed by immunohistochemistry (IHC).
  • For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC.
  • Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+/3+ IHC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →